nanotech investing Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer 23h
nanotech investing Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer 15 September
